Archer-Daniels-Midland Co vs Nuwellis Inc — how do they compare? Archer-Daniels-Midland Co trades at $80.75 (market cap $38.79B), while Nuwellis Inc trades at $1.49 (market cap $522.76K). The key difference: Archer-Daniels-Midland Co is far larger — about 74202.3× Nuwellis Inc's market cap, and Archer-Daniels-Midland Co pays a 2.58% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| ADM | NUWE | |
|---|---|---|
Market Cap | $38.79B | $522.76K |
Sector | Consumer Staples | Technology |
52-Week High | $87.32 | $220.50 |
52-Week Low | $56.00 | $1.42 |
Enterprise Value | $47.04B | -$1.29M |
Dividend Yield | 2.58% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NUWE trades at $1.49, down 8.59% over the past day, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025, with a negative net income margin of -217.22%, though it has shown revenue growth and recent strategic expansions in pediatric care. A recent 35:1 reverse stock split was executed on June 26, 2026.
The outlook remains high-risk due to persistent losses and cash burn, but growth initiatives and new product development offer potential. Key risks include execution challenges and dependence on financing. Analyst sentiment is mixed, with a 50% buy and 50% hold rating among covered analysts.
Trailing returns across standard periods
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →